Casali R, Simmons R L, Ferguson R M, Mauer M M, Kjellstrand C M, Buselmeier T J, Najarian J S
Ann Surg. 1976 Aug;184(2):145-54. doi: 10.1097/00000658-197608000-00002.
From January 1, 1968 to December 31, 1973, 50 patients received two or more kidney transplants. Patient and graft survival was highly dependent upon the source of the donor and to a lesser extent the functional duration of the first transplant and the elapsed time between first and second graft. Survival (patient and graft) was best in patients receiving two related grafts and worst in patients receiving two sequential cadaver grafts. Intermediate rates of success followed cadaver transplantation after rejection of a related graft. The highest failure rate was encountered when those patients who sustained an early loss of the first cadaver graft received a subsequent cadaver graft within a few months. We recommended removal of the acutely rejected graft and delay prior to retransplantation of patients who rapidly reject cadaver grafts in the face of maximal doses of immunosuppression. A delay will permit recovery from both the immunosuppression and any underlying subclinical infections, and will permit the recognition of anti-HL-A antibodies which may not be manifest soon after rejection. Retransplantation of the patient who is slowly rejecting the first kidney does not require prior removal of the rejected graft or delay in retransplantation.
1968年1月1日至1973年12月31日期间,50例患者接受了两次或更多次肾移植。患者和移植物的存活高度依赖于供体来源,在较小程度上依赖于首次移植的功能持续时间以及首次和第二次移植之间的间隔时间。接受两次亲属供体移植的患者存活率(患者和移植物)最佳,而接受两次连续尸体供体移植的患者存活率最差。亲属供体移植排斥后进行尸体移植的成功率处于中等水平。当首次尸体供体移植早期失功的患者在几个月内接受后续尸体供体移植时,失败率最高。我们建议,对于在最大剂量免疫抑制情况下迅速排斥尸体供体移植的患者,应切除急性排斥的移植物并在再次移植前延迟一段时间。延迟一段时间将使患者从免疫抑制和任何潜在的亚临床感染中恢复过来,并有助于识别可能在排斥反应后不久未表现出来的抗人白细胞抗原(anti-HL-A)抗体。缓慢排斥首次移植肾的患者再次移植时,不需要事先切除排斥的移植物或延迟再次移植。